Literature DB >> 19211378

Extravasation of oxaliplatin: an infrequent and irritant toxicity.

C Pericay1, A López, J R Soler, T Bonfill, E Dotor, E Saigí.   

Abstract

Oxaliplatin has been classified as an irritant drug. Less than 10 cases of oxaliplatin extravasation through a central venous access have been described to date. We present a case of extravasation through a central venous access, of the highest dose (165 mg) of oxaliplatin reported to date. We confirmed the irritant effect, and full recovery from toxicity was achieved. We describe the treatment administered and offer a review of literature.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19211378     DOI: 10.1007/s12094-009-0324-z

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  11 in total

1.  Extravasation of Oxaliplatin (Eloxatin((R))) - Clinical Course.

Authors:  M. Baur; H.-R. Kienzer; T. Rath; C. Dittrich
Journal:  Onkologie       Date:  2000-10

Review 2.  Extravasation: a dreaded complication of chemotherapy.

Authors:  D L Schrijvers
Journal:  Ann Oncol       Date:  2003       Impact factor: 32.976

3.  Extravasations of oxaliplatin.

Authors:  Albrect Kretzschmar; Daniel Pink; Peter Thuss-Patience; Bernd Dörken; Peter Reichert; Robert Eckert
Journal:  J Clin Oncol       Date:  2003-11-01       Impact factor: 44.544

Review 4.  Extravasation of systemic hemato-oncological therapies.

Authors:  R A Ener; S B Meglathery; M Styler
Journal:  Ann Oncol       Date:  2004-06       Impact factor: 32.976

Review 5.  Vesicant extravasation part II: Evidence-based management and continuing controversies.

Authors:  Rita Wickham; Constance Engelking; Carmel Sauerland; Dominick Corbi
Journal:  Oncol Nurs Forum       Date:  2006-11-27       Impact factor: 2.172

Review 6.  Vesicant extravasation part I: Mechanisms, pathogenesis, and nursing care to reduce risk.

Authors:  Carmel Sauerland; Constance Engelking; Rita Wickham; Dominick Corbi
Journal:  Oncol Nurs Forum       Date:  2006-11-27       Impact factor: 2.172

Review 7.  Extravasation management.

Authors:  Lisa Schulmeister
Journal:  Semin Oncol Nurs       Date:  2007-08       Impact factor: 2.315

8.  A case report of oxaliplatin extravasation.

Authors:  K F Foo; M Michael; G Toner; J Zalcberg
Journal:  Ann Oncol       Date:  2003-06       Impact factor: 32.976

Review 9.  Management of extravasation of oxaliplatin.

Authors:  Mário L de Lemos; Susan Walisser
Journal:  J Oncol Pharm Pract       Date:  2005-12       Impact factor: 1.809

10.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Authors:  A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

View more
  1 in total

1.  Cervical dissecting extravasation of oxaliplatin: A case report.

Authors:  Jorge Hernando; Judit Riera-Arnau; Maria Roca; Alejandro Garcia; Jaume Capdevila
Journal:  Mol Clin Oncol       Date:  2022-01-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.